Boehringer Ingelheim Vetmedica, Inc. has announced that Dr. Albrecht Kissel, as its new president and CEO. Kissel will resume responsibilities over U.S. domestic sales and marketing, research and development, and manufacturing operations for BIVI, effective Sept. 1.
With nearly two decades of experience in the animal health industry, Kissel has been an integral part of Boehringer Ingelheim's success. He began his career with BI in sales and marketing and has led teams in Germany, Austria, Southeast Asia and China. In 2002 he was named Global Head of Business Development and charged with growing the animal health business through mergers and acquisitions, including the most recent acquisition of certain assets of Fort Dodge Animal Health.
"Dr. Kissel has always demonstrated excellent leadership qualities," said George Heidgerken, Kissel's predecessor, who recently was named Head of Corporate Division Animal Health. "He will continue to grow our business and tenaciously seek opportunities to bring value to our customers."
Most recently as vice president, Americas, Kissel created and implemented business strategies for Canada, the United States, Mexico, Australia, New Zealand, Southern Africa and all countries in South America.
"Dr. Kissel has a vast amount of experience in the animal health industry, which will only aid in his ability to lead BIVI in coming years," Heidgerken said.
Kissel, a native of Germany, will be relocating to the St. Joseph area with his family. "I look forward to the many opportunities that lie ahead," he said. "We continue to invest in personnel, facilities and technology, while pursuing our mission to improve productivity for livestock producers and the quality of life for companion animals and their owners."
Boehringer Ingelheim Vetmedica, Inc., St. Joseph, is a subsidiary of Boehringer Ingelheim Corporation based in Ridgefield, Conn., and a member of the Boehringer Ingelheim group of companies, Ingelheim, Germany.